B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis
In Vivo · 2025
DOI: 10.21873/invivo.13920 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Ece Akbayir und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Aziz Sancar Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkiye; ece.akbayir@atlas.edu.tr. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B-Lymphocytes, T-Lymphocytes, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treatment of multiple sclerosis. The aim of this study was to explore the utility of peripheral blood cell subsets in prediction of treatment response to ocrelizumab in relapsing remitting multiple sclerosis (RRMS). PATIENTS AND METHODS: Thirty-one patients with RRMS resistant to first-line immunomodulating agents were enrolled and followed-up for 12 months under ocrelizumab treatment. Disease activity was monitored by 6-monthly assessments of Expanded Disability Status Scale and cranial-spinal magnetic resonance imaging. No evidence of disease activity (NEDA-3) status was determined, and peripheral blood mononuclear cells were immunophenotyped by flow cytometry. RESULTS: Peripheral blood populations of CD19+ B-cells, plasma cells and CD3+ CD20+ T-cells decreased under ocrelizumab therapy, whereas populations of switched memory B-cells, CD4+ T-cells, naïve T-cells and regulatory B-1a and CD49d+ T-cells were increased. NEDA-3 status was achieved by 19 patients, who exhibited elevated baseline populations of regulatory CD49d+ T- and B-1a-cells, reduced post-treatment (month 6 or 12) populations of switched memory B-cells, and increased post-treatment populations of naïve T-cells. Month 12 Expanded Disability Status Scale scores correlated positively with plasmablast and naïve T-cell populations. CONCLUSION: Response to ocrelizumab is linked to baseline regulatory and post-treatment effector B- and T-cell subset populations. Memory B-cells appear to be a marker of treatment efficacy for ocrelizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Aziz Sancar Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkiye; ece.akbayir@atlas.edu.tr.
- Department of Language and Speech Therapy, Faculty of Health Sciences, Istanbul Atlas University, Istanbul, Turkiye.
- Department of Neurology, Istanbul Haydarpasa Numune Training and Research Hospital, Istanbul, Turkiye.
- Department of Neuroscience, Aziz Sancar Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkiye.
Zitieren
APA
Akbayir, E., Kizilay, T., Erol, R., Ozkan-Yasargun, D., Tuzun, E., Yilmaz, V., & Turkoglu, R. (2025). B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis. In Vivo. https://doi.org/10.21873/invivo.13920
Vancouver
Akbayir E, Kizilay T, Erol R, Ozkan-Yasargun D, Tuzun E, Yilmaz V, et al. B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis. In Vivo. 2025. doi:10.21873/invivo.13920
BibTeX
@article{Akbayir2025,
author = {Akbayir, Ece and Kizilay, Tugce and Erol, Ruziye and Ozkan-Yasargun, Duygu and Tuzun, Erdem and Yilmaz, Vuslat and Turkoglu, Recai},
title = {B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13920}
}
EUVIMED